Dynavax Technologies (NASDAQ:DVAX) Sets New 1-Year High – What’s Next?

Dynavax Technologies Co. (NASDAQ:DVAX)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $14.05 and last traded at $13.73, with a volume of 398164 shares trading hands. The stock had previously closed at $13.33.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DVAX shares. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday.

Dynavax Technologies Stock Up 2.7 %

The firm’s fifty day moving average is $12.81 and its 200-day moving average is $11.99. The stock has a market capitalization of $1.80 billion, a PE ratio of 105.51 and a beta of 1.32. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. On average, equities research analysts predict that Dynavax Technologies Co. will post 0.2 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DVAX. E Fund Management Co. Ltd. grew its holdings in shares of Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 771 shares during the period. Summit Investment Advisors Inc. grew its holdings in Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 904 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 1,169 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.